Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cellectis S.A. ADR (NQ: CLLS )

3.015 +0.005 (+0.17%)
Streaming Delayed Price Updated: 11:20 AM EST, Jan 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 34,767
Open 2.960
Bid (Size) 2.990 (1)
Ask (Size) 3.040 (2)
Prev. Close 3.010
Today's Range 2.900 - 3.015
52wk Range 1.830 - 6.740
Shares Outstanding 45,484,310
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
7 CRISPR Stocks With the Best Long-Term Potential
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. 
Via InvestorPlace
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
From Cellectis Inc.
Via Globe NewsWire

Performance

YTD
+32.82%
+32.82%
1 Month
+32.82%
+32.82%
3 Month
+21.33%
+21.33%
6 Month
+0.50%
+0.50%
1 Year
-51.45%
-51.45%

More News

Read More
Why Is Calyxt (CLXT) Stock Up 140% Today?
Via InvestorPlace
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
From Cellectis Inc.
Via Globe NewsWire
Cellectis Touts Positive Preliminary Data From Two Leukemia Trials
Via Benzinga
5 Most Expensive Health Care Stocks You Should Worry About
Via Benzinga
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Tesla Shares Are Trading Lower; Here Are 32 Stocks Moving Premarket
Via Benzinga
Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases
From Cellectis Inc.
Via Globe NewsWire
Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities
From Cellectis Inc.
Via Globe NewsWire
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
From Cellectis Inc.
Via Globe NewsWire
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?
Via Investor's Business Daily
Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML
From Cellectis Inc.
Via Globe NewsWire
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
From Cellectis Inc.
Via Globe NewsWire
Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022
From Cellectis Inc.
Via Globe NewsWire
Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)
From Cellectis Inc.
Via Globe NewsWire
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022
From Cellectis Inc.
Via Globe NewsWire
Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022
From Cellectis Inc.
Via Globe NewsWire
Cellectis's Earnings Outlook
Via Benzinga
Cellectis to Report Third Quarter 2022 Financial Results
From Cellectis Inc.
Via Globe NewsWire
Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022
From Cellectis Inc.
Via Globe NewsWire
Why Missfresh Shares Are Trading Lower; Here Are 30 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
From Cellectis Inc.
Via Globe NewsWire
Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer
From Cellectis Inc.
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.